Philip Stevens

Philip Stevens
Executive Director
Geneva Network

Philip founded Geneva Network in 2015.

His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues.

Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant.

He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK).

He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.

Recent Publications

May 26, 2020

Health data and digital technologies will be essential for improving global health outcomes beyond the COVID-19 pandemic. Low- and middle-income nations, with fledgling digital health strategies and many barriers to overcome, stand to benefit the most.

April 18, 2020

With two-thirds of the world in lockdown and no clear way out of the novel coronavirus crisis, it’s increasingly obvious that biopharmaceutical innovation will play a pivotal role.

February 5, 2020

Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.

February 3, 2020

Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.

April 15, 2019

Seven case studies showcase how IP rights are enabling innovators in Latin America to help solve some of the greatest global health challenges.

May 9, 2017

The Trump administration’s trade strategy has largely taken aim at unfair trade practices in traditional industries. Yet, as Philip Stevens and Nigel Cory explain in The Hill, foreign actors are threatening another major component of the U.S. economy that we hear much less about: the theft of knowledge and IP in a wide variety of traditional and high-tech sectors.

Recent Events and Presentations

May 24, 2021

ITIF and Geneva Network hosted a discussion on the role of IP rights in vaccine and therapeutic R&D, manufacturing, and preparedness for future pandemics. Panelists from around the world will discuss the best ways to scale up mass vaccine and therapeutic manufacturing and examine the implications that would arise from a global waiver of IP rights.